|
1
|
Singer CS, Deutschman CS, Seymour CW,
Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche
JD, Coopersmith CM, et al: The third international consensus
definitions for sepsis and septic shock (Sepsis-3). JAMA.
315:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rudd KE, Delaney A and Finfer S: Counting
sepsis, an imprecise but improving science. JAMA. 318:1228–1229.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rhodes A, Evans LE, Alhazzani W, Levy MM,
Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally
ME, et al: Surviving sepsis campaign: International guidelines for
management of sepsis and septic shock: 2016. Crit Care Med.
45:486–552. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shankar-Hari M, Phillips GS, Levy ML,
Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD and
Singer M; Sepsis Definitions Task Force, : Developing a new
definition and assessing new clinical criteria for septic shock:
For the third international consensus definitions for sepsis and
septic shock (Sepsis-3). JAMA. 315:775–787. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van der Poll T, van de Veerdonk FL,
Scicluna BP and Netea MG: The immunopathology of sepsis and
potential therapeutic targets. Nat Rev Immunol. 17:407–420. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seeley EJ and Bernard GR: Therapeutic
targets in sepsis: Past, present, and future. Clin Chest Med.
37:181–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hotchkiss RS, Monneret G and Payen D:
Immunosuppression in sepsis: A novel understanding of the disorder
and a new therapeutic approach. Lancet Infect Dis. 13:260–268.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dellinger RP: Severe sepsis trials: Why
have they failed? Minerva Anestesiol. 65:340–345. 1999.PubMed/NCBI
|
|
9
|
Gotts JE and Matthay MA: Sepsis:
Pathophysiology and clinical management. BMJ. 353:i15852016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seymour CW and Rosengart MR: Septic shock:
Advances in diagnosis and treatment. JAMA. 314:708–717. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McLean AS, Tang B and Huang SJ:
Investigating sepsis with biomarkers. BMJ. 350:h2542015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vashist SK, Venkatesh AG, Marion Schneider
E, Beaudoin C, Luppa PB and Luong JH: Bioanalytical advances in
assays for C-reactive protein. Biotechnol Adv. 34:272–290. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ridker PM: A test in context:
High-sensitivity c-reactive protein. J Am Coll Cardiol. 67:712–723.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Póvoa P, Coelho L, Almeida E, Fernandes A,
Mealha R, Moreira P and Sabino H: Pilot study evaluating C-reactive
protein levels in the assessment of response to treatment of severe
bloodstream infection. Clin Infect Dis. 40:1855–1857. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fraunberger P, Wang Y, Holler E, Parhofer
KG, Nagel D, Walli AK and Seidel D: Prognostic value of interleukin
6, procalcitonin, and C-reactive protein levels in intensive care
unit patients during first increase of fever. Shock. 26:10–12.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schneider CP, Yilmaz Y, Kleespies A, Jauch
KW and Hartl WH: Accuracy of procalcitonin for outcome prediction
in unselected postoperative critically ill patients. Shock.
31:568–573. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chousterman BG, Swirski FK and Weber GF:
Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol.
39:517–528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mikacenic C, Price BL, Harju-Baker S,
O'Mahony DS, Robinson-Cohen C, Radella F, Hahn WO, Katz R,
Christiani DC, Himmelfarb J, et al: A Two-biomarker model predicts
mortality in the critically III with Sepsis. Am J Respir Crit Care
Med. 196:1004–1011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi Y, Ge J, Ma C, Wu N, Cui X and Liu Z:
Activin A regulates activation of mouse neutrophils by Smad3
signalling. Open Biol. 7:1603422017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ettinger M, Calliess T, Kielstein JT,
Sibai J, Brückner T, Lichtinghagen R, Windhagen H and Lukasz A:
Circulating biomarkers for discrimination between aseptic joint
failure, low-grade infection, and high-grade septic failure. Clin
Infect Dis. 61:332–341. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buttaro MA, Tanoira I, Comba F and
Piccaluga F: Combining C-reactive protein and interleukin-6 may be
useful to detect periprosthetic hip infection. Clin Orthop Relat
Res. 468:3263–3267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elgeidi A, Elganainy AE, Abou Elkhier N
and Rakha S: Interleukin-6 and other inflammatory markers in
diagnosis of periprosthetic joint infection. Int Orthop.
38:2591–2595. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rung J and Brazma A: Reuse of public
genome-wide gene expression data. Nat Rev Genet. 14:89–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maslove DM and Wong HR: Gene expression
profiling in sepsis: Timing, tissue, and translational
considerations. Trends Mol Med. 20:204–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wong HR: Clinical review: Sepsis and
septic shock-the potential of gene arrays. Crit Care. 16:2042012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang BM, Huang SJ and McLean AS:
Genome-wide transcription profiling of human sepsis: A systematic
review. Crit Care. 14:R2372010. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Parnell GP, Tang BM, Nalos M, Armstrong
NJ, Huang SJ, Booth DR and McLean AS: Identifying key regulatory
genes in the whole blood of septic patients to monitor underlying
immune dysfunctions. Shock. 40:166–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koch L, Linderkamp O, Ittrich C, Benner A
and Poeschl J: Gene expression profiles of adult peripheral and
cord blood mononuclear cells altered by lipopolysaccharide.
Neonatology. 93:1–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41(Database Issue):
D991–D995. 2013.PubMed/NCBI
|
|
30
|
Benjamini Y, Drai D, Elmer G, Kafkafi N
and Golani I: Controlling the false discovery rate in behavior
genetics research. Behav Brain Res. 125:279–284. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rhee SY, Wood V, Dolinski K and Draghici
S: Use and misuse of the gene ontology annotations. Nat Rev Genet.
9:509–515. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Munoz-Torres M and Carbon S: Get GO!
Retrieving GO data using AmiGO, QuickGO, API, Files, and tools.
Methods Mol Biol. 1446:149–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45(D1): D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Trinchieri G: Type I interferon: Friend or
foe? J Exp Med. 207:2053–2063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kan B, Razzaghian HR and Lavoie PM: An
immunological perspective on neonatal sepsis. Trends Mol Med.
22:290–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schreiber G and Piehler J: The molecular
basis for functional plasticity in type I interferon signaling.
Trends Immunol. 36:139–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
LeMessurier KS, Häcker H, Chi L, Tuomanen
E and Redecke V: Type I interferon protects against pneumococcal
invasive disease by inhibiting bacterial transmigration across the
lung. PLoS Pathog. 9:e10037272013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mancuso G, Midiri A, Biondo C, Beninati C,
Zummo S, Galbo R, Tomasello F, Gambuzza M, Macrì G, Ruggeri A, et
al: Type I IFN signaling is crucial for host resistance against
different species of pathogenic bacteria. J Immunol. 178:3126–3133.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mahieu T, Park JM, Revets H, Pasche B,
Lengeling A, Staelens J, Wullaert A, Vanlaere I, Hochepied T, van
Roy F, et al: The wild-derived inbred mouse strain SPRET/Ei is
resistant to LPS and defective in IFN-beta production. Proc Natl
Acad Sci USA. 103:pp. 2292–2297. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dejager L, Vandevyver S, Ballegeer M, Van
Wonterghem E, An LL, Riggs J, Kolbeck R and Libert C:
Pharmacological inhibition of type I interferon signaling protects
mice against lethal sepsis. J Infect Dis. 209:960–970. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weighardt H, Kaiser-Moore S, Schlautkötter
S, Rossmann-Bloeck T, Schleicher U, Bogdan C and Holzmann B: Type I
IFN modulates host defense and late hyperinflammation in septic
peritonitis. J Immunol. 177:5623–5630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schwandt T, Schumak B, Gielen GH,
Jüngerkes F, Schmidbauer P, Klocke K, Staratschek-Jox A, van
Rooijen N, Kraal G, Ludwig-Portugall I, et al: Expression of type I
interferon by splenic macrophages suppresses adaptive immunity
during sepsis. EMBO J. 31:201–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
McNab F, Mayer-Barber K, Sher A, Wack A
and O'Garra A: Type I interferons in infectious disease. Nat Rev
Immunol. 15:87–103. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ginsburg AS, Meulen AS and Klugman KP:
Prevention of neonatal pneumonia and sepsis via maternal
immunisation. Lancet Glob Health. 2:e679–e680. 2014. View Article : Google Scholar : PubMed/NCBI
|
